What is Moderna?
Moderna operates at the intersection of biotechnology and advanced digital medicine. By leveraging messenger RNA (mRNA) to instruct human cells to produce proteins that prevent or treat disease, the company has established a dominant market position. Its portfolio spans a diverse range of therapeutic areas, including rare diseases, autoimmune conditions, and oncology. As a pioneer in the field, Moderna continues to refine its delivery mechanisms, ensuring that its mRNA-based medicines provide scalable, high-impact solutions for global health challenges.
The company's growth has been supported by a sophisticated mix of institutional capital, government grants, and corporate partnerships. This diversified funding strategy has allowed Moderna to transition from a research-heavy startup into a commercial-stage powerhouse capable of rapid clinical development and global distribution.
How much funding has Moderna raised?
Moderna has raised a total of $8.1B across 19 funding rounds:
Other Financing Round
$25M
Other Financing Round
$450M
Multiple Rounds
$502M
Multiple Rounds
$1.2B
Multiple Rounds
$2.8B
Other Financing Round
$750M
Multiple Rounds
$2.1B
Other Financing Round (2014): $25M featuring Alexion Pharmaceuticals
Other Financing Round (2015): $450M backed by RA Capital Management, Viking Global Investors, Alexion Pharmaceuticals, Invus, AstraZeneca, and Wellington Management
Grant (2016): $20M with participation from Bill & Melinda Gates Foundation
Other Financing Round (2016): $474M led by Invus, Wellington Management, RA Capital Management, Viking Global Investors, AstraZeneca, and Alexion Pharmaceuticals
Grant (2016): $8M supported by BARDA
Other Financing Round (2018): $500M featuring Viking Global Investors, ArrowMark Partners, EDBI, Pictet Private Equity Investors S.A., BB Biotech Ventures, Fidelity Management & Research Company, Sequoia Capital China, ADIA, Alexandria Venture Investments, and Julius Baer Group
Corporate Investment (2018): $125M backed by Merck
Stock Issuance/Offering (2018): $604.3M, investors not publicly disclosed
Stock Issuance/Offering (2020): $500M, investors not publicly disclosed
Grant (2020): $483M supported by BARDA
Stock Issuance/Offering (2020): $1.3B, investors not publicly disclosed
Grant (2020): $472M, investors not publicly disclosed
Other Financing Round (2024): $750M with participation from Blackstone
Other Financing Round (2025): $590M led by Biomedical Advanced Research and Development Authority (BARDA
Debt (2025): $1.5B supported by Ares Management Corporation
Unspecified (2025): $54.3M, investors not publicly disclosed
Key Investors in Moderna
Flagship Pioneering
Founded in 1999 and headquartered in Cambridge, Massachusetts, Flagship Pioneering is a company of pioneering scientists and professionals that build companies that transform human health and sustainability.
Merck
Founded in 1891 and headquartered in Rahway, NJ, Merck & Co., Inc. is a global healthcare company delivering innovative solutions through prescription medicines, biologic therapies, vaccines, and animal health products.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools.
What's next for Moderna?
With the infusion of $54.3M, Moderna is well-positioned to accelerate its late-stage clinical trials and expand its manufacturing infrastructure. The current lifecycle stage, characterized by major enterprise-level funding, suggests a strategic pivot toward long-term sustainability and the diversification of its therapeutic pipeline. Investors are likely to monitor the company's ability to translate its mRNA platform into new modalities, particularly in the fields of personalized cancer vaccines and rare genetic disorders. As the company matures, the focus will shift toward optimizing operational efficiency and maintaining its competitive edge in the rapidly evolving biopharmaceutical landscape.
See full Moderna company page
